Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex Q4 revenue rises 10% to $3.19 billion; 2026 guidance $12.95 to $13.1 billion

Positive Impact 3 of 5 earnings Written later

Vertex reported fourth-quarter 2025 total revenue of $3.19 billion, up 10% from a year earlier, and GAAP net income of $1.19 billion, or $4.65 per diluted share, compared with $913 million, or $3.50 per diluted share, in the fourth quarter of 2024. The company also gave full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, which shareholders can compare with future results.

Key points

  • Q4 2025 GAAP net income was $1.19 billion, or $4.65 per diluted share, versus $913 million, or $3.50 per diluted share, in Q4 2024.
  • Full year 2025 total revenue was $12.0 billion, up 9%, and GAAP net income was $3.95 billion, compared with a GAAP net loss of $536 million in 2024.
  • 2026 guidance: total revenue of $12.95 billion to $13.1 billion and GAAP R&D, AIPR&D and SG&A expenses of $6.3 billion to $6.45 billion.

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECFeb 12, 2026, 4:04 PM ET
Accession number0000875320-26-000034

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.